Abstract
Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. Th......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
